We investigated the four above-mentioned ABCB1 SNPs in MM patients enrolled in the Rev II clinical trial of second-line Len-based treatment [17], and the impact of these polymorphisms on treatment response, hematological adverse events (AEs), and survival. This evidence concerns the gene ABCB1 and Miyoshi myopathy.